


# Excise duty framework for cannabis products

<https://policybase.cma.ca/link/policy13799>

POLICY TYPE Response to consultation  
DATE 2017-12-07  
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

## Documents

---




# Non-prescription availability of low-dose codeine products

<https://policybase.cma.ca/link/policy13734>

|             |   |
|-------------|---|
| POLICY TYPE | Response to consultation                      |
| DATE        | 2017-11-7                                     |
| TOPICS      | Pharmaceuticals, prescribing, cannabis, drugs |

## Documents

---




# Bill C-45: The Cannabis Act

<https://policybase.cma.ca/link/policy13723>

|             |   |
|-------------|---|
| POLICY TYPE | Parliamentary submission                      |
| DATE        | 2017-08-18                                    |
| TOPICS      | Pharmaceuticals, prescribing, cannabis, drugs |

## Documents

---



# CMA response to patented medicines regulations consultations

<https://policybase.cma.ca/link/policy13690>

POLICY TYPE Response to consultation  
DATE 2017-06-28  
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

## Documents



# Canada's lower-risk cannabis use guidelines (LRCUG)

<https://policybase.cma.ca/link/policy13726>

POLICY TYPE Policy endorsement  
DATE 2017-05-26  
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

## Documents



# CMA's Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers' Health Act and to make consequential amendments to other Acts

<https://policybase.cma.ca/link/policy13641>

|             |   |
|-------------|---|
| POLICY TYPE | Parliamentary submission  |
| DATE        | 2017-04-07  |
| TOPICS      | Health care and patient safety<br>Pharmaceuticals, prescribing, cannabis, drugs |

## Documents

---




# CMA submission to the study of Bill C-37

<https://policybase.cma.ca/link/policy13617>

POLICY TYPE Parliamentary submission  
DATE 2017-04-06  
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

## Documents

---



# Consultation on the renewal of Federal Tobacco Control Strategy

<https://policybase.cma.ca/link/policy13804>

POLICY TYPE Response to consultation  
DATE 2017-04-05  
TOPICS Health care and patient safety  
Pharmaceuticals, prescribing, cannabis, drugs

## Documents



# Position statement on prescription drug shortages in Canada

<https://policybase.cma.ca/link/policy10756>

|               |   |
|---------------|---|
| POLICY TYPE   | Policy document                               |
| LAST REVIEWED | 2017-03-04                                    |
| DATE          | 2013-05-25                                    |
| TOPICS        | Pharmaceuticals, prescribing, cannabis, drugs |

## Documents

ASSOCIATION  
MEDICAL  
CANADIAN  
POLICE  
ASSOCIATION

**CMA POLICY**

### Position Statement on Prescription Drug Shortages in Canada

The escalation in shortages of prescription drugs in the past few years and the ongoing disruptions to supply experienced in Canada and globally are matters of grave concern to the Canadian Medical Association (CMA) and its members. Drug shortages are having a detrimental impact on the delivery of patient care and treatment and the availability of health care services across the country.

CMA has advocated for a thorough examination of the drug supply system to identify points where risk in Canada can influence supply problems. Solutions will have to tackle the various players in the drug supply chain, from manufacturers through to health care providers and levels of government.

#### Background

Drug shortages are not a problem confined to Canada. In the United States the number of drug shortages from 2000 to 2010 grew by more than 200 per cent. In 2011, 251 shortages were reported to the FDA. Canada has not had an accurate count of the number of drugs in short supply over past years but in April 2013, 273 drugs were listed on the industry sponsored Canada Drug Shortage Monitor.

Factors that influence the occurrence of a drug shortage can occur at any stage of the drug supply chain and any disruptions can ripple through the system.

**Figure 1: Drug Supply Chain in Canada**

© 2013 Canadian Medical Association. All rights reserved. For more information on copyright or to obtain a copy of this document, please contact the CMA. This document is provided for personal use only and is not to be distributed, reproduced, or used in any way that may cause harm or offense. All other rights reserved. For more information on copyright or to obtain a copy of this document, please contact the CMA. This document is provided for personal use only and is not to be distributed, reproduced, or used in any way that may cause harm or offense. All other rights reserved.